Summary henri termeer and tomye tierney discuss genzyme's gaucher initiative and the steps they took to serve both genzyme's humanitarian commitment and their commercial objectives and convince the egyptian government to authorize reimbursement for the drug cerezyme. Genzyme center (c) case study solution, genzyme center (c) case study analysis, subjects covered environmental protection facilities innovation project evaluation social responsibility by michael w toffel, aldo sesia source: harvard b. Bibliographic record and links to related information available from the library of congress catalog information from electronic data provided by the publisher may be incomplete or contain other coding. The co-founder and ceo of startechcom are reviewing his company's strategic plan, including an aggressive goal of $150 million in sales in three years the firm must leverage its knowledge to develop a significant existence in europe, to achieve this aim.
In egypt, genzyme humanitarian commitment to treat all sufferers of the rare gaucher disease world's first commercial imperative raises her to the huge investments required to pay for the drug cerezyme bring to market. They believe that as long as the gaucher initiative-genzyme's partnership with project hope-is providing free cerezyme, they will be unable to convince the egyptian government to authorize. This case is accompanied by a video short that can be shown in class or included in a digital coursepack instructors should consider the timing of making the video available to students, as it.
Subjects covered business & government relations business policy developing countries market entry negotiation social responsibility values by christopher a bartlett. Case 8-2: genzyme's gaucher initiative: global risk and responsibility birth of the company - genzyme began by focusing on supplying raw materials, enzymes, fine chemicals, etc, to large research labs and pharmaceutical companies - founded in 1981 by henry blair laying the foundation - blair obtained a contract to manufacture and supply the. Genzymes csr dilemma: how to play its hand case study solution, genzymes csr dilemma: how to play its hand case study analysis, subjects covered business & government relations developing countries international business social responsibility strategic alliances by christopher a ba. Sanofi genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Paralleling its domestic commitment to provide treatment to all gaucher sufferers, in 1998 the company lahed a global version of cap called the gaucher initiative with the objective of delivering treatment to those in less developed countries.
Bartlett, christopher a, and andrew n mclean genzyme's gaucher initiative: global risk and responsibility chap 22 in problems and cases in health care marketing, edited by john t gourville, john a quelch, and v kasturi rangan, 411-434 new york: mcgraw-hill/irwin, 2004. Genzymes csr dilemma: how to play its hand case analysis, genzymes csr dilemma: how to play its hand case study solution, genzymes csr dilemma: how to play its hand xls file, genzymes csr dilemma: how to play its hand excel file, subjects covered business & government relations developing countries international business social responsibility strategic alliances by christopher a ba. Teaching note for (9-303-048) teaching note | | december 2002 (revised october 2006. Professor quelch is the author, co-author or editor of twenty books, including the global market (2004), global marketing management (4th edition, 1999), cases in advertising and promotion management (4th edition, 1996) and the marketing challenge of europe 1992 (2nd edition, 1991. Please click on the choices below to learn more about this product genzyme's gaucher initiative: global risk and responsibility author(s): christopher a bartlett and andrew n mclean.
Together they laid down few strategic principles that would guide the company's future activities (i) commitment to building a diversified portfolio of targeted products and defined markets, with focus on niches where needs were largely unmet. Genzyme's gaucher initiative risk & responsibility conclusion company background information founded in 1981 henry blair & sheridan synder blair relocated to england. In 1991 genzyme's first gaucher treatment, ceredase, was approved on the basis of a 12-patient pivotal trial, with the dose and the total number of patients enrolled being chosen primarily on the basis of the amount of enzyme the company had available. Gaucher disease is an inherited condition affecting fewer than 10,000 people worldwide people with gaucher disease do not have enough of the enzyme, β-glucosidase (glucocerebrosidase) leading to the accumulation of its substrate, glucosylceramide.
The approval of cerdelga is encouraging for gaucher patients because it is a first-line oral treatment that has demonstrated a positive risk/benefit profile, making it important from both a scientific and a clinical perspective, said dr pramod mistry, md, phd, professor of medicine and pediatrics and the director of national gaucher.